Format

Send to

Choose Destination
See comment in PubMed Commons below
J Med Chem. 2004 Dec 16;47(26):6439-42.

2,3-diaminopyridine bradykinin B1 receptor antagonists.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, Pennsylvania 19486, USA. scott_d_kuduk@merck.com

Abstract

Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.

PMID:
15588075
DOI:
10.1021/jm049394l
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center